Ginkgo biloba for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Nicolaï, Saskia P A ^a   Kruidenier, Lotte M ^b   Bendermacher, Bianca L W ^b   Prins, Martin H ^a   Stokmans, Rutger A ^a,b   Broos, Pieter P H L ^b   Teijink, Joep A W ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT; VASODILATOR AGENT;

ANKLE BRACHIAL INDEX; BLEEDING; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATURIA; HUMAN; INTERMITTENT CLAUDICATION; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN ALLERGY; SYSTEMATIC REVIEW; TREADMILL TEST; VISUAL ANALOG SCALE; WALKING SPEED; GINKGO BILOBA; META ANALYSIS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

GINKGO BILOBA; HUMANS; INTERMITTENT CLAUDICATION; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84891692089     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006888.pub3     Document Type: Review

References (56)

1. Bauer U. 6-Month double-blind randomised clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforschung 1984;34(6):716-20.
2. Blume J, Kieser M, Holscher U. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication]. Vasa 1996;25(3):265-74.
3. Blume J, Kieser M, Hölscher U. Ginkgo-special-extract EGb 761 in peripheral arterial occlusive diseases stage IIb according to Fontaine. Fortschritte der Medizin 1998;116(35-6):36-7.
4. Bulling B, von Bary S. Treatment of chronic peripheral occlusive disease with physical training and ginkgo biloba extract 761 [Behandlung der chronischen peripheren arteriellen Verschlusskrankheit met physikalischem Training und Ginkgo-biloba-Extrakt 761, Ergebnisse einer placebokontrollierten Doppelblindstudie]. Medizinische Welt 1991;42(8):702-8.
5. Diehm C, Heinrich F, Mörl H. Placebo-controlled, multicentre, randomised, double-blind pilot study examining the effectiveness of Ginkgo biloba extract EGb 761® in patients with Fontaine stage IIb peripheral aterial disease [Placebokontrollierte, multizentrische, randomisierte, doppelblinde Pilotstudie zur Prüfung der Wirksamkeit des Ginkgo-biloba-Extraktes EGb 761® bei Patienten mit peripherer arterieller Verschlusskrankheit im Stadium IIb nach Fontaine]. Internal report. Dr. Willmar Schwabe GmbH & Co. 1990.
6. Drabaek H, Petersen JR, Winberg N, Hansen KF, Mehlsen J. The effect of Ginkgo biloba extract in patients with intermittent claudication. Ugeskrift for Laeger 1996;158(27):3928-31.
7. Gardner CD, Taylor-Piliae RE, Kiazand A, Nicholus J, Rigby AJ, Farquhar JW. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral arterial disease: a randomized clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention 2008;28(4):258-65.
8. Mouren X, Caillard P, Schwartz F. Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPO2 determination. Angiology 1994;45(6):413-7.
9. Natali J. Protocol for a study comparing Ginkgo biloba extract and placebo in patients with arteriopathy of the lower extremities [Protocole d'étude de l'extrait de Ginkgo biloba face au placebo dans l'artéropathie des membres inférieurs]. Internal Study Report, Ipsen, Paris 1985.
10. Peters H, Kieser M, Holscher U. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial. Vasa 1998;27(2):106-10.
11. Salz H. The effectiveness of a Ginkgo biloba preparation in arterial ischemic diseases of the leg. Controlled double-blind cross-over study. Therapie der Gegenwart 1980;119(11):1345-56.
12. Schoop W, Breddin K, Diehm C, Grub J, Held K, Horsch S, et al.Clinical test with ginkgo biloba EGb 761 extract for patients with peripheral arterial occlusive disease stage IIb fontaine in comparison with placebo [Klinische prufung mit ginkgo biloba-spezialextrakt EGb 761 bei patienten mit peripherer arterieller verschlusskrankheit im stadium IIb nach fontaine im vergleich zu placebo]. Vasa 1997;26(160):P15.
13. Thomson GJL, Vohra RK, Carr MH, Walker MG. A clinical trial of gingko biloba extract in patients with intermittent claudication. International Angiology 1990;9(2):75-8.
14. Wang J, Zhou S, Bronks R, Graham J, Myers S. Supervised exercise training combined with ginkgo biloba treatment for patients with peripheral arterial disease. Clinical Rehabilitation 2007;21(7):579-86.
15. Ambrosi C, Bourde C. A new therapeutic intervention arteriopathies of the lower extremities: Tanakan. Clinical trial and study of liquid crystals [Nouveauté thèrapeutique médicinale dans les artériopathies des membres d'inferieur: Tanakan. Essai clinique et étude par les cristaux liquides]. Gazette médicale de France 1975;82(6):628-33.
16. Baitsch G. Treatment of obliterative arterial disease in diabetics Fontaine's stage IV with moist gangrene, an open randomized trial of Ginkgo-biloba extract Roekan vs. Dextran 40. Clinical Trials Journal 1986;23(1):11-9.
17. Berndt ED, Kramer M. Medicational therapy of peripheral arterial occlusive disease in stage IIb [Medikamentöse Therapie der peripheren arteriellen Verschlusskrankheit im Staium IIb]. die Therapiewoche 1986;37:2815-9.
18. Bohmer D, Kalinski S, Michaelis P, Szogy A. Efficacy and tolerance of Ginkgo biloba extract compared to that of pentoxifylline in the treatment of patients suffering from peripheral chronic arterial occlusive disease. Hers Kreislauf 1988;20(1):5-8.
19. Courbier R, Jausseran JM, Reggi M. Double blind, cross over trial of Tanakan in arteriopathies of the lower extremities [Étude à double insu croisée du Tanakan dans les arteriopathies des membres inférieurs]. Méditerranée Médicale 1977;126:61-4.
20. Frileux C, Cop R. Concentrated extract of Ginkgo biloba in peripheral vascular disorders [L'extrait concentré de Ginkgo biloba dans les troubles vasculaires périphériques]. Cahiers d'Artériologie de Royat 1975;3:117-22.
21. Garzya G, Picari M. Treatment of peripheral vasculopathies with Ginkgo biloba extract [Trattamento della vasculopatie periferiche con una nuova sostanza estrattiva: il Tanakan]. Clinica Europea 1981;20(5):936-44.
22. Horsch S, Holscher U. Infusion therapy with ginkgo biloba special extract EGb 761 in patients with PAOD fontaine stages III and IV - A reference- controlled double-blind clinical trial. Munchener Medizinische Wochenschrift 1998;140(16):232-6.
23. Li AL, Shi YD, Landsmann B, Schanowski-Bouvier P, Dikta G, Bauer U, et al.Hemorheology and walking of peripheral arterial occlusive diseases patients during treatment with Ginkgo biloba extract. Acta pharmacologica Sinica 1998;19(5):417-21.
24. d stage arteriopathies. A preliminary study [Studio sull'efficiaca dell'estratto di ginkgo biloba, magnesio e levo-arginina nel trattamento dei pazienti arteriopatici al II stadio]. Minerva Cardioangiologica 1998;46(9):319-20.
25. Rudofsky G. Effect of Ginkgo biloba extract in cases of arterial occlusive disease. Randomized placebo controlled crossover study. Fortschritte der Medizin 1987;105(20):397-400.
26. Saudreau F, Serise JM, Pillet J, Maiza D, Mercier V, Kretz JG, et al.Efficiency of Ginkgo-biloba extract in treatment of stages III (fontaine classification) chronic occlusive arterial diseases of the lower limbs. Journal des Maladies Vasculaires 1989;14(3):177-82.
27. Schweizer J, Hautmann C. Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb: A randomised, double-blind, multicentric clinical trial. Arzneimittel-Forschung 1999;49(11):900-4.
28. Antithrombotic Trialist's Collaboration (ATC). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. British Medical Journal 2002;324(7329):71-86.
29. Bauer U. Ginkgo biloba extract in the treatment of arteriopathy of the lower extremities. A 65 week trial. Presse Medicale 1986;15(31):1546-9.
30. Bauer U. A two-year study of ginkgo biloba extract in the treatment of peripheral arterial disease (Fontaine stage IIb). What is New in Angiology? Trends and Controversies. Zuckschwerdt, W, 1986:531-2.
31. Bauer U. Long-term treatment of the peripheral arterial clasp illness with Ginkgo biloba extract (GBE); a 3-year-investigation [Langzeitbehandlung der peripheren arteriellen Verschlusskrankheit met Ginkgo biloba Extrakt (GBE); eine 3-Jahres-Untersuchung]. Vasa 1986;15:S26.
32. Bendermacher BLW, Willigendael EM, Teijink JAW, Prins MH. Medical management of peripheral arterial disease. Journal of Thrombosis & Haemostasis 2005;3(8):1628-37.
33. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005263.pub2]
34. de Backer TL, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD000988.pub3]
35. De Backer TLM, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD001368.pub3]
36. Fontaine R, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta 1954;5/6:499-533.
37. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384-92.
38. Girolami B, Bernardi E, Prins MH, ten Cate JW, Hettiarachchi R, Prandoni P, et al.Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl. A meta-analysis. Archives of Internal Medicine 1999;159(4):337-45.
39. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006;295(5):547-53.
40. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Chichester: The Cochrane Collaboration, 2008.
41. Hooi JD, Stoffers HEJH, Kester ADM, Rinkens PELM, Kaiser V, van Ree JW, et al.Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusion disease. The Limburg PAOD study. Peripheral Arterial Occlusive Disease. Scandinavian Journal of Primary Health Care 1998;16(3):177-82.
42. Horsch S, Walther C. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD) - a review based on randomized, controlled studies. International Journal of Clinical Pharmacology and Therapeutics 2004;42(2):63-72.
43. Kleijnen J, Knipschild P. Ginkgo biloba. The Lancet 1992;340(8828):1136-9.
44. Korth R, Nunez D, Bidault J, Benveniste J. Comparison of three paf-acether antagonist ginkgolides. European Journal of Pharmacology 1988;152(1-2):101-10.
45. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000990]
46. Letzel H, Schoop W. Gingko biloba extract EGb 761 and pentoxifylline in intermittent claudication. Secondary analysis of the clinical effectiveness [Ginkgo-biloba-Extrakt EGb 761 und Pentoxifyllin bei Claudicatio intermittens. Sekundaranalyse zur klinischen Wirksamkeit]. VASA 1992;21(4):403-10.
47. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arteriosclerosis, Thrombosis & Vascular Biology 1998;18(2):185-92.
48. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000;59(5):1057-70.
49. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. American Heart Journal 2002;143(6):961-5.
50. Pincemail J, Dupuis M, Nasr C, Hans P, Haag-Berrurier M, Anton R, et al.Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia 1989;45(8):708-12.
51. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. The American journal of medicine 2000;108(4):276-81.
52. Robak J, Gryglewski RJ. Flavonoids are scavengers of superoxide anions. Biochemical Pharmacology 1988;37(5):837-41.
53. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD003748.pub3]
54. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al.Recommended standards for reports dealing with lower extremity ischemia: revised version. Journal of Vascular Surgery 1997;26(3):517-38.
55. Schneider B. Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled clinical studies [Ginkgo-biloba-Extraxt bei peripheren arteriellen Verschlusskrankheiten; Meta-analyse von kontrolierten klinischen Studien]. Arzneimittel-Forschung 1992;42(4):428-36.
56. Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Teijink JA. Ginkgo biloba for intermittent claudication. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006888.pub2]